Screener
ADMA Biologics ADMA Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Three Months ended June 30, 2026 | Three Months ended June 30, 2025 | Six Months ended June 30, 2026 | Six Months ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | (3,424) | (1,834) | (5,524) | (3,809) |
| Loss on extinguishment of debt | - | (1,159) | - | (1,159) |
| Other expense | (22) | (108) | (161) | (172) |
| Other income (expense), net | (2,208) | (2,701) | (3,354) | (4,132) |
| INCOME BEFORE INCOME TAXES | 50,237 | 40,097 | 107,365 | 73,546 |
| Provision for income taxes | 12,415 | 5,878 | 24,215 | 12,424 |
| NET INCOME | $$37,822 | $34,219 | $83,150 | 61,122 |
| BASIC EARNINGS PER COMMON SHARE | $$0.17 | $0.14 | $0.36 | 0.26 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's other income (expense)?
- ADMA Biologics (ADMA) reported other income (expense) of -$2.21M in Q2 2026.
- How has ADMA Biologics's other income (expense) changed year-over-year?
- ADMA Biologics's other income (expense) increased by 18.3% year-over-year, from -$2.7M to -$2.21M.
- What is the long-term trend for ADMA Biologics's other income (expense)?
- Over 4 years (2021 to 2025), ADMA Biologics's other income (expense) has grown at a -9.8% compound annual growth rate (CAGR), from -$13.27M to -$8.79M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about ADMA Biologics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude